Heart-on-a-Chip mimics drug response seen in Humans

The platform allows the testing of conditions that cannot be easily replicated in animals. Researchers from TARA Biosystems and GlaxoSmithKline (GSK) have published data demonstrating that TARA’s engineered heart-on-a-chip system replicated drug responses found in adult humans. The findings, published in the Journal of Toxicological Sciences, show TARA’s 3D-cardiac tissue platform can predict how human hearts will

Read More


This Drug Will Save Children’s Lives. It Costs $2 Million. NYT Editorial board position

Safety, innovation and affordability need not be mutually exclusive goals for cutting-edge treatments. Source NYT Spinal muscular atrophy is a condition often fatal by age 2. Babies with the disorder have a rare genetic mutation that prevents the nervous system from controlling certain muscles. As they grow to be toddlers, these children struggle to move their limbs,

Read More


Profiling the stem-cell characters in the story of stomach lining renewal

Source Institute of Molecular Biotechnology (IMBA) Using an unbiased labeling technique, mathematical modeling, and single cell profiling to trace the footsteps of stem cells and their daughters, researchers at the University of Cambridge (UK), DGIST (S.Korea), and IMBA (Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Austria) have confirmed that two populations of

Read More


New Frontiers of Corneal Gene Therapy

Source https://www.liebertpub.com/doi/pdf/10.1089/hum.2019.026#utm_source=ETOC&utm_medium=email&utm_campaign=hum Corneal diseases are among the most prevalent causes of blindness worldwide. The transparency and clarity of the cornea are guaranteed by a delicate physiological, anatomic, and functional balance. For this reason, all the disorders, including those of genetic origin, that compromise this state of harmony can lead to opacity and eventually vision loss.

Read More


European Medicines Agency validates marketing application for Filgotinib for the treatment of rheumatoid arthritis

Gilead Sciences and Galapagos announced that the Marketing Authorization Application (MAA) for filgotinib, an investigational, oral, selective JAK1 inhibitor, for the treatment of adults with rheumatoid arthritis (RA) has been validated and is now under evaluation by the European Medicines Agency (EMA). “We are excited about the validation of this application which is an important

Read More


Virtual and augmented reality can save lives by improving surgeons’ training Justin Barad position

Source STAT Rapid advances in the development of medical devices in the 21st century are contributing to healthier lives, but bring with them a new challenge: teaching clinicians how to use these often-complicated technologies. Teaching them poorly, or failing to do it at all, can negate the potential benefits and put patients at risk of

Read More